SCINTIX™ therapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
SELF-DRIVING RADIOTHERAPY
Cancer is talking. We’re listening.
When radiopharmaceuticals are introduced into the body, cancer cells absorb them and create a biological beacon, which our machine uses to manage motion and treat solid tumors of any stage disease.
Our SCINTIX technology delivers high doses of radiation to tumors, even those in motion. Live targeting allows for greater impact to the tumor and potentially less dose to surrounding tissues.
Most patients with stage four cancer are not considered candidates for definitive radiotherapy. Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer.
Treatment isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. Adding SCINTIX therapy to chemotherapy, immunotherapy and targeted drugs may potentially improve outcomes.
Each cancer’s unique biology provides second-by-second information to direct radiotherapy Company to host live stream YouTube event today at 10:30 AM PST HAYWARD, Calif., Feb. 2, 2023 – RefleXion Medical, a therapeutic oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted the first marketing clearance for its SCINTIX™ biology-guided radiotherapy, a […]
Sam Mazin wandered into a lecture at Stanford University 15 years ago, and today his company said it walked away with $80 million for a machine aimed at zapping tough-to-treat, late-stage cancers.
Booth #3745 in the exhibit hall at ASTRO’s annual conference in San Antonio, Texas, was bustling with activity. Thousands of radiation oncologists convene at ASTRO each year to learn and share advances in radiotherapy planning and treatment. Conference attendees stopped by to ask questions and watch demonstrations of RefleXion Medical’s X1 platform. For the first […]